Articles | Volume 6, issue 9
https://doi.org/10.5194/jbji-6-413-2021
https://doi.org/10.5194/jbji-6-413-2021
Original full-length article
 | 
12 Nov 2021
Original full-length article |  | 12 Nov 2021

Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study

Tom A. G. Van Vugt, Jeffrey Heidotting, Jacobus J. Arts, Joris J. W. Ploegmakers, Paul C. Jutte, and Jan A. P. Geurts

Viewed

Total article views: 888 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
674 173 41 888 19 22
  • HTML: 674
  • PDF: 173
  • XML: 41
  • Total: 888
  • BibTeX: 19
  • EndNote: 22
Views and downloads (calculated since 12 Nov 2021)
Cumulative views and downloads (calculated since 12 Nov 2021)

Viewed (geographical distribution)

Total article views: 825 (including HTML, PDF, and XML) Thereof 825 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 27 Mar 2024
Download
Short summary
Chronic osteomyelitis is a bone infection and was treated with a combination of antibiotics and two surgeries. With the introduction of the biomaterial S53P4 bioactive glass, these infections can be treated with antibiotics and one surgery. This study shows 85 % success in the treatment of these bone infections. Together with the fundamentally different antibacterial mechanisms without antibiotic resistance, S53P4 bioactive glass is recommendable for the treatment of these infections.